Enpatoran (TLR7/8 inhibitor) in SLE & CLE - helps skin, others? - suppresses interferon lowest dose was highest response though (upsetting primary endpoint) Promising, watch for the ph3 No photos allowed, but official slides: https://t.co/1yX6XrYvKH #EULAR2025 LB0004 @RheumNow

APEX study Ph3 RCT Guselkumab In BioNaive active PsA w/ erosions>=2 wk 24 ACR20 GUS Q4W 67% Q8W 68% vs PBO 47% Less Rx progression in both Q4W & Q8W vs. PBO #EULAR2025 @RheumNow LB0010 https://t.co/OVDWWECtOZ

💉Early results from a dose-escalation trial of novel CD19xCD3xCD28 trispecific antibody (CC312) in refractory #SLE show no ICANS or ≥G2 CRS, rapid B cell depletion & 100% SRI-4 response (n=5). @RheumNow #EULAR2025 #LB0007 #CART

#EULAR2025 Abstr#LB0005 Phase IIb RCT in moderate #Sjogren reported significant reduction in ESSDAI at WK24 from BL in HCQ-Leflunomide vs PBO. CRESS & STAR improved. No significant difference in UWS, Schirmer, & ESSPRI. Future work: cohort of high symptom burden @RheumNow

The relation between RA, comorbidities and presenteism NRAS survey 891 RA pts 75% had at least one comorbidity Absenteeism more likely if One OR = 1.68 or Two OR = 2.26 comorbid conditions In particular Anxiety OR = 2.39 Depression OR = 1.75 Osteoarthritis OR = 1.85 Back

The transformative potential of integrating ePROMs into AI care pathways 🔺️Study by Dr Antoni Chan et al. achieved a new-to-followup ratio of 1:2.5 outperforming the national average of 1:4.2 🔺️Without losing contact with pts @synovialjoints POS1271 #EULAR2025 @RheumNow https://t.co/z3jO3ADHR1

🦵🏻SAP-001, a novel uricosuric targeting a non-URAT1 renal transporter, lowered sUA <6 mg/dL in up to 79% of patients with refractory #gout on b/g xanthine oxidase inhibitor. >50% on 60 mg/day reached sUA <3 mg/dL. 💊Potential new oral ULT option. @RheumNow #EULAR2025 #LB0008 https://t.co/dfY1V5sHSh

Why do Rheumatologists shift to private practice? Are there gender based differences? A survey of 100+ European rheumatologists Female 🚺 rheumatologists: Leave hospital earlier At a lower hierarchical level Reasons for leaving: nightshifts unfair promotion decisions

EULAR PtC for definition of #TR Trt Refractory) #Psoriatic_Arthritis #D2M 1️⃣ Failure >= 2 b/tsDMARDs 2️⃣ Problematic 3️⃣ Evidence of persistent dis + 4️⃣ Exclude drivers like comorbidities & psychosocial factors 🔺️Exclude failure due to Side Effets/CI #EULAR2025 @RheumNow https://t.co/ULD2Xe6p6A

Will climate change impact rheumatological care? #EULAR2025 @rheumnow Especially larger cities are are affected more. Need to worry about comorbidities https://t.co/KhTyAssGeI